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Introduction
Colorectal cancer is one of the leading causes of death in
the Western world; its incidence is lower only than those
of breast cancer in women and lung cancer in men.
Radical surgery can cure only about 50% of patients [1].
Adjuvant chemotherapy is beneficial in 10% to 15% of
high-risk patients with UICC stage III disease [2, 3].
It is estimated that more than 80% of the patients
with metastatic disease have liver involvement either at
the time of first diagnosis or at relapse after curative
surgery [4]. The liver is the sole site of metastases in
up to 30% of patients, of whom one-third may be resect-
able [5].
The probable therapy choices are no treatment ('wait-
and-see'), locoregional treatment such as surgical resec-
tion, alcohol instillation, laser-induced hyperthermia,
locoregional chemotherapy or systemic chemotherapy.
Only a limited amount of information is available about
the natural course of patients with liver metastasis only.
Depending on the extent of the liver involvement (soli-
tary vs. non-solitary lesions) a median survival of 11 or
17 months has been reported, which corresponds to a
three-year survival rate of 10% to 13%, respectively [6].
However, no data from a randomized trial are available
because most clinicians have been unwilling to expend
unequal amounts of effort in the care of their patients, an
attitude that is supported by the results of recent medi-
cal and surgical treatment. Data on laser-induced hyper-
thermia or percutaneous alcohol injection [7-9] are too
preliminary and will not be discussed in this paper.
Favorable results (five-year survival rate of 38%)
reported after the resection of hepatic metastases in a
series of 456 consecutive patients associated with low
mortality and morbidity rates (3% and 31%, respectively)
led the authors to conclude that a randomized trial to
investigate the efficacy of surgical resection - as opposed
to no resection - can not ethically be performed [10].
This article will discuss the therapeutic alternatives in
the care of patients with isolated liver metastases.
The value of surgical resection
Following the first report by Langenbuch in 1887 on
liver resection [11] the procedure has become a safe one
due to better supportive treatment and improvements in
the operating technique. It is now a well accepted treat-
ment for patients with colorectal liver metastases, which
may be curative in approximately 30% of patients [10,
12-22]. These single-center retrospective analyses are
supported by registry data including over 1500 patients
[23, 24].
Although a radical (RO) resection may be possible in
about 70% of patients, tumor relapse will occur in at
least two out of three of them. Detailed information
about the pattern of recurrences is available from the
pooled data of an American, British and German regis-
try database [23] (Figure 1). Interestingly, approximately
43% of resected patients will experience a recurrence in
the liver either as the only site or in combination with
other sites. About 27% of the patients will develop
extrahepatic metastases with no effect on the liver. This
data indicates that most of the patients will have intra-
or extrahepatic occult disease already at the time of
surgery which will constitute the source of relapse. It
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Figure 1. Pattern of recurrence within five years after resection of
colorectal cancer hepatic metastases (according to [23]).
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Table I. Retrospective analysis of liver resection.
Number of
patients
141
75
62
60
80
122
100
207
280
110
204
456
Registry data
Recruitment
period
1948-1982
1971-1982
1950-1981
1975-1985
1970-1985
1981-1989
1980-1989
1960-1988
1960-1987
1984-1992
1981-1991
1985-1991
Number of patients Recruitment
607
1568
1948-1985
1968-1990
Synchroneous
~ 25%
~29%
55%
22%
54%
39%
n.a.
47%
38%
23%
73%
n.a.
period
Solitary
~ 75%
n.a.
68%
63%
53%
52%
n.a.
54%
62%
62%
45%
53%
Number of sites
38
16
Extra hepatic
disease
8%
15%
0%
0%
0%
n.a.
n.a.
13%
3%
7%
n.a.
10%
Five-year overall survival
33%
28%
Operative
mortality
4%
7%
10%
0%
5%
4%
5%
6%
4%
5%
0%
3%
Reference
[23]
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Five-year
overall survival
25%
35%
34%
45%
25%
30%
30%
31%
25%
30%
32%
38%
Reference
[12]
[13]
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[15]
[16]
[17]
[18]
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has been speculated that the liver resection itself may
stimulate hepatic mitotic activity through growth factors
for liver regenerative functions and that these factors
might promote tumor growth after partial hepatectomy,
as has been demonstrated in experimental studies [25].
To identify patients at high risk for intra- or extra-
hepatic failure is, therefore, of major importance. A
French group has collected information on 1, 568 pa-
tients undergoing hepatic surgery for colorectal cancer
metastases [24]. Derived from a multivariate analysis the
following variables associated with an unfavorable prog-
nosis have been identified: age above 60 years, extension
into serosa or lymphatic spread of the primary cancer,
time interval from primary tumor to metastases of less
than two years, size of the largest metastases greater
than 5 cm, more than three hepatic metastases and
surgical clearance of less than one centimeter. A CEA
level of greater than 5 mg/1 or greater than 30 mg/1 may
be used as a substitute variable for age. Patients with up
to two of these factors had a low risk of recurrence and a
two-year survival rate of 79% which decreased to 56% in
instances of three or four risk factors and to 34% in
instances of five or more risk factors. In the latter cohort
survival of longer than five years was rare and the value
of surgery may be debatable.
The role of adjuvant postoperative chemotherapy
The success of adjuvant systemic chemotherapy after
curative resection of the primary tumor [2, 3] has
rekindled interest in its use after resection of hepatic
metastases. Various attempts have been made using
intraarterial, portal vein, peritoneal, systemic chemo-
or immunotherapy to improve the cure rate of patients
by the use of adjuvant chemotherapy [13, 26-37]. In
some of these pilot studies a positive effect on survival
was claimed, so at least four randomized multicenter
trials were initiated comparing i.v. or HAI 5-FU/FA or
FUDR versus a control group or systemic 5-FU treat-
ment [21]. A randomized trial conducted by the Arbeits-
gemeinschaft fur Lebermetastasen (ALM) in Germany
investigated the role of hepatic arterial infusion (HAI)
after liver resection [38]. A total of 226 patients have
been randomized to receive 5-FU (1000 mg/m2/day/five
days) plus folinic acid (200 mg/m2/day/five days) or no
further chemotherapy. At 18 months' median observa-
tion time the recurrence rate in the liver was 33% with
and 37% without adjuvant treatment (P = 0.715). This
first interim analysis demonstrated a median survival of
35 months versus 41 months without postoperative HAI
(P = 0.15) The study was closed because the relative risk
of death was at best reduced by 15% and at worst
doubled by the application of adjuvant treatment.
Because of low patient accrual, the European Organ-
ization for Research and Treatment of Cancer (EORTC),
in collaboration with the NCI Canada, have unfortu-
nately discontinued the randomization of patients after
hepatic surgery to receive either 5-FU plus folinic acid
(Mayo-Clinic regimen) or no treatment until develop-
ment of metastases.
The value of locoregional or systemic chemotherapy in
patients with liver metastases
Patients for whom surgery is not suitable are frequently
offered locoregional or systemic chemotherapy. It is
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generally accepted that such a cohort of patients com-
prises a more favorable subgroup than patients with
more widespread disease, but comprises a more unfav-
orable cohort than those with resectable lesions. Com-
parison of the treatment results obtained with chemo-
therapy to those yielded by surgery is hampered by the
differences in patient population.
It is debatable whether local regional therapy is more
beneficial than systemic chemotherapy with respect to
patient prognosis [39]. Proponents of this method claim
for it the high objective tumor response rate of approx-
imately 50%, which is significantly higher than the
approxmately 20% achieved by systemic treatment with
modulated 5-FU bolus regimens [40, 41]. Some trials
also reported a significantly prolonged response dura-
tion and time to intrahepatic failure. However, a survival
benefit could only be demonstrated in the trials that
compared intrahepatic treatment with best supportive
care with or without the addition of systemic treatment
at some time during the course of the disease [42-44].
The recently reported results achieved with systemic
chemotherapy question the value of locoregional treat-
ment. With schedules using infusional 5-FU, a response
rate of approximately 40%-50% together with a median
survival approaching 20 months [39, 45, 46] was re-
ported. Retrospective analysis of patients with liver
metastases only who were nevertheless receiving sys-
temic chemotherapy rather than regional treatment re-
vealed an at least similar outcome with respect to re-
sponse rate and median survival [39]. This regimen also
showed promise when used intraarterially rather than
systemically [47]. An ongoing Medical Research Council
(MRC) trial in collaboration with researchers from the
EORTC is comparing the value of high-dose bi-weekly
48-hour infusional 5-FU given either as HAI or sys-
temically. Locoregional treatment should only be given
within the framework of a clinical trial or after failure of
systemic treatment in selected patients.
The value of surgery as opposed to chemotherapy in
patients with colorectal cancer hepatic metastases was
investigated in 24 patients with multiple but resectable
liver metastases randomized to complete resection and
adjuvant HAI or HAI only [36]. In this small study
survival did not improve in patients with resection over
that of the cohort treated by HAI only.
To gain a clearer idea of the merits of systemic or
locoregional chemotherapy as relative to those of surgi-
cal resection in patients with colorectal liver metastases,
it might be useful to select patients receiving chemo-
therapy rather than surgery, according to the prognostic
factors designated in the French registry. We identified
50 patients with colorectal cancer hepatic metastases
and at least five of the risk factors according to Nord-
linger et al. [24]. This group received high-dose infu-
sional 5-FU modulated by interferon or folinic acid [46],
and the 50 patients had a two-year survival rate of 28%.
It was determined that modulation with folinic acid was
more effective than the combination with interferon [46].
A total of 29 patients received this therapy and had a
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Figure 2. Survival of patients receiving high-dose infusional 5-FU
with colorectal cancer metastases confined to the liver and five or
more risk factors according to Nordlinger [24]. —- 29 patients receiv-
ing weekly 24-hour infusional 5-FU plus folinic acid; — 21 patients
receiving weekly 24-hour infusional 5-FU plus interferon.
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Figure 3 Survival of 94 patients receiving locoregional chemotherapy
via the hepatic artery for colorectal cancer metastases confined to the
liver and five or more risk factors according to Nordlinger [24].
two-year survival rate of 40%, which compares favor-
ably with the patients that underwent surgery (Figure 2).
Another cohort of 94 patients received regional ther-
apy via the hepatic artery as described previously [48].
This group of patients also matched the high-risk group
according to Nordlinger (Figure 3). The two-year sur-
vival rate of 33% is very close to the one reported for
individuals with hepatic resection. These data are re-
markable because they were obtained in patients for
whom surgery was not suitable because of extensive
non-resectable disease.
Discussion
About 50% of patients with colorectal cancer are cured
by surgery alone. Patients with tumor involvement of
regional lymph nodes additionally benefit from adjuvant
systemic chemotherapy. Patients with resectable liver
[24] or lung metastases [49] can, according to the retro-
spective reports, expect a five-year survival (not disease-
free survival) rate of about 30% and with an Ro resec-
tion of about 15% [50].
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To compare the relative effectiveness of surgery and
locoregional or systemic chemotherapy in patients with
isolated liver metastases is difficult because the patient
cohorts differ substantially. Individuals suitable for sur-
gery are generally referred to specialized centers and
represent a highly selected subgroup with technically or
medically operable liver lesions that are preoperatively
rigorously staged and further selected at laparotomy to
exclude extrahepatic spread. Fong et al. [10] found that
10% of patients for whom liver resection was planned
actually had extrahepatic disease detected only at lapa-
rotomy. In patients who did not qualify for resection due
to more widespread disease, but for whom locoregional
chemotherapy was deemed suitable, the incidence of
extrahepatic tumor detected at laparotomy was 20%-
25% [51-53]. If we consider successful surgery as a
'response' to treatment surgeons have a failure rate of
only about 10% in selection of possible responders prior
to treatment, while medical oncologists fail well over
50% of the time. Although cure of malignancy is
claimed for surgical resection of colorectal liver metas-
tasis, the survival curves do not show a plateau even
after a follow-up period of 5 or more years. Neverthe-
less, resection of liver metastasis is a safe procedure
which is associated with low mortality in specialized
centers. Even if the patient is not cured the quality of
life is generally high after resection and only reduced
postoperatively for six to 10 days if no complications
occur, while patients given chemotherapy will be treated
for several months. Therefore, surgery is the treatment
of choice for patients with good prognostic factors.
Whether surgery should be considered the preferred
treatment also in patients with a strong chance of recur-
rence remains to be demonstrated. Our retrospective
data indicates that these patients may also be adequately
treated by systemic chemotherapy.
Another interesting experience has been reported by
Bismuth et al. [54]. A total of 330 patients with colo-
rectal cancer liver metastases were initially unresectable
for various reasons and underwent the systemic applica-
tion of 5-FU, folinic acid plus oxaliplatin. A radical
resection was possible in 53 patients. The cumulative
three- and five-year survival rates were 54% and 40%,
respectively. This experience reflects the superior activ-
ity of the new generation of chemotherapies for patients
with colorectal cancer. We should therefore consider
chemotherapy a powerful tool within a multidiciplinary
concept for patients with metastatic disease. The combi-
nation of systemic chemotherapy and excellent surgery
appears to be a promising approach. Therefore, a Ger-
man-French trial of combined preoperative chemo-
therapy followed by surgery in patients with high-risk
hepatic metastases (Nordlinger score >4) has been
initiated under the auspicious of the EORTC.
It is to be hoped that identification of subgroups, by
the use of molecular markers or specific properties of
tumors such as thymidilate synthase expression, will
render it possible for us to individualize the treatment
of this heterogeneous disease.
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